Pharmaceutical Preparations · DE · CIK 1472012
Develops targeted oncology therapies, including antibody-drug conjugates, to improve cancer patient outcomes
Comparable business profile · signals at a glance
In the 90 days to Mar 27, 2026: 2 insiders bought $644K · 1 sold $1.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 27, 2026 | Siegall Clay BPresident and CEO | Buy | 25,450 | $19.67 | $501K |
| Mar 23, 2026 | Wagenheim PhilipDirector | Sell | 28,200 | $20.65 | $582K |
| Mar 20, 2026 | Wagenheim PhilipDirector | Sell | 36,800 | $20.47 | $753K |
| Mar 11, 2026 | Bienaime Jean JacquesDirector | Buy | 1,000 | $21.55 | $22K |
| Mar 10, 2026 | Bienaime Jean JacquesDirector | Buy | 1,000 | $22.12 | $22K |
| Dec 30, 2025 | Siegall Clay BPresident and CEO | Buy | 4,729 | $21.15 | $100K |
| Dec 22, 2025 | Barchas IsaacDirector | Sell | 371,949 | $21.72 | $8.1M |
| Dec 22, 2025 | Barchas IsaacDirector | Sell | 11,251 | $22.34 | $251K |
| Dec 19, 2025 | Tsai PhilipChief Technical Officer | Buy | 10,000 | $20.49 | $205K |
| Dec 19, 2025 | Siegall Clay BPresident and CEO | Buy | 7,278 | $20.48 | $149K |
| Dec 18, 2025 | Siegall Clay BPresident and CEO | Buy | 46,511 | $21.50 | $1000K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.